Calliditas
Stockholm, SE · 3 known investors
Find your way into Calliditas
Calliditas is a biopharmaceutical company developing and commercializing treatments for renal and other conditions, including TARPEYO/Nefecon/Kinpeygo (budesonide) for primary IgA nephropathy and NOX inhibitor candidates such as setanaxib for fibrotic diseases and cancer. It works with commercial partners including Everest Medicines and STADA to bring its therapies to markets such as the US, UK, EU, and China.
Investors · 3
In the news
Frequently asked questions
- What does Calliditas do?
- Calliditas is a biopharmaceutical company developing and commercializing treatments for renal and other conditions, including TARPEYO/Nefecon/Kinpeygo (budesonide) for primary IgA nephropathy and NOX inhibitor candidates such as setanaxib for fibrotic diseases and cancer. It works with commercial partners including Everest Medicines and STADA to bring its therapies to markets such as the US, UK, EU, and China.
- Who are Calliditas's investors?
- Calliditas's investors include Industrifonden, Sofinnova Partners, Kreos Capital.
- Where is Calliditas headquartered?
- Calliditas is headquartered in Stockholm, SE.